Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736440 | 1.00 | POLB (0.46) | POLBALDH1A1LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL14110335 | 0.85 | KMT2A (0.55) | POLBALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL738506 | 0.85 | KMT2A (0.55) | POLBALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL737342 | 0.85 | PDE7A (0.43) | ALDH1A1CYP2C9PDE7AKMT2AMEN1 | |
| SCHEMBL14110362 | 0.85 | PDE7A (0.43) | ALDH1A1CYP2C9PDE7AKMT2AMEN1 | |
| SCHEMBL736430 | 0.82 | ALDH1A1 (0.53) | POLBALDH1A1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL19174810 | 0.82 | KMT2A (0.55) | POLBALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL738916 | 0.82 | ALDH1A1 (0.53) | POLBALDH1A1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL736393 | 0.80 | SIRT6 (0.52) | POLBALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL736445 | 0.80 | PTK2 (0.51) | POLBALDH1A1LMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | POLB 3177/4885ALDH1A1 731/4885LMNA 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.